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Abstract
Long Interspersed Nuclear Elements (L1s or LINEs) are the most abundant retrotransposons in the human genome,
and they comprise approximately 17% of DNA. L1 retrotransposition can be mutagenic, and deleterious insertions
both in the germ-line and in somatic cells have resulted in disease. Recently, an assay was developed to monitor
L1 retrotransposition in cultured human cells. This assay, for the first time, now allows for a systematic study of
L1 retrotransposition at the molecular level. Here, I will review progress made in L1 biology during the past three
years. In general, I will limit the discussion to studies conducted on human L1s. However, interesting parallels to
rodent L1s and other non-LTR retrotransposons also will be discussed.
Introduction
Transposable elements are DNA sequences that can
move (i.e., transpose) from one genomic location to
another, and they are present in the genomes of virtu-
ally all eukaryotes. There are two general classes of
transposable elements: transposons and retrotranspo-
sons. Transposons mobilize via a DNA intermediate
and can transpose by a cut and paste, conservat-
ive, or replicative mechanisms (Bender & Kleckner,
1986; Kleckner, 1990). Retrotransposons mobilize via
an RNA intermediate and transpose by a replicative
mechanism termed retrotransposition (Boeke et al.,
1985).
Retrotransposons can be subdivided into two gen-
eral classes: Long-terminal repeat (LTR) and non-LTR
retrotransposons. Autonomous LTR-retrotransposons,
typified by the yeast Ty1 element, possess LTRs
and resemble retroviruses in both their structure
and replication mechanism (Boeke & Corces, 1989).
However, LTR retrotransposons do not have an ex-
tracellular phase in their replication cycle because
their envelope gene (Env) is either non-functional or
absent.
Non-LTR retrotransposons (or poly A retrotrans-
posons) lack LTRs and usually terminate in a poly-
adenylic acid (poly A) or short A-rich tail (Hutchison
et al., 1989). They are a diverse group that includes the
abundant mammalian long interspersed nuclear ele-
ments (LINEs or L1s), the CR1-like elements of birds
and reptiles, the R1 and R2 elements of insects, the
jockey, I, F, and G elements fromDrosophila, and
the Cin4 element ofArabidopsis thaliana(Xiong &
Eickbush, 1988a). The reverse transcriptases (RTs) en-
coded by non-LTR retrotransposons also are related to
the RTs encoded by retroplasmids fromNeurospora
crassa(Kuiper & Lambowitz, 1988), bacterial retrons
(Lampson, Inouye & Inouye, 1991), mobile group
II introns from yeast mitochondria (Kennell et al.,
1993; Moran et al., 1995) and bacteria (Matsuura
et al., 1997), and the catalytic subunit of telomerase
(Nakamura & Cech, 1998). Thus, although quite
different in structure, it appears that non-LTR retro-
transposons share a common, ancient evolutionary
ancestor.
The human genome also contains numerous cop-
ies of short interspersed nuclear elements (SINEs)
and processed pseudogenes (Okada, 1991; Smit, 1996;
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Deininger & Batzer, 1999). Many SINEs (e.g., Alu
elements and tRNA-derived SINEs) and all processed
pseudogenes structurally resemble non-LTR retro-
transposons because they lack LTRs and introns, ter-
minate in a polyA tail, and are flanked by variable-
length target site duplications. However, SINEs and
processed pseudogenes are non-autonomous retro-
transposons because neither class of element encodes
proteins that are required for their mobility.
We recently developed an assay to monitor
L1 retrotransposition in cultured mammalian cells
(Moran et al., 1996). The advent of this assay has
allowed for the identification of retrotransposition-
competent L1s (RC-L1s) in both the human and mouse
genomes (Sassaman et al., 1997; DeBerardinis et al.,
1998; Naas et al., 1998), and has yielded a number
of unexpected findings about the impact of L1 retro-
transposition on mammalian genomes (Moran et al.,
1999a). Here, I will review progress made in L1
biology during the past three years.
Human L1s: Structure and abundance
L1s comprise approximately 17% of human DNA and
are the most abundant retrotransposons in the gen-
ome (Smit, 1996). The overwhelming majority of L1s
are unable to retrotranspose because they are 5′ trun-
cated, rearranged or mutated (Grimaldi, Skowronski &
Singer, 1984; Hutchison et al., 1989). However, an es-
timated 30–60 human L1s remain retrotransposition-
competent (RC-L1s) (Sassaman et al., 1997). Human
RC-L1s are 6.0 kb and contain a 5′ untranslated re-
gion (UTR) that harbors an internal promoter (Kurose
et al., 1995; Minakami et al., 1992; Swergold, 1990),
two non-overlapping open reading frames (ORF1 and
ORF2) (Scott et al., 1987), and a 3′ UTR that ends
in a poly A tail (Figure 1). In addition, L1s usually
are flanked by variable-length target site duplications
(Hutchison et al., 1989).
In vitro biochemical studies revealed that human
ORF1 encodes a 40 kDa site-specific RNA binding
protein (p40) that co-localizes with L1 RNA in cyto-
plasmic ribonucleoprotein particles (RNPs) (Hohjoh
& Singer 1996, 1997; Holmes et al., 1992). RNAse
T1 mapping experiments demonstrated that p40 binds
two related AT-rich sites in L1 RNA. The first binding
site is located just downstream of the putative ORF2
initiation codon between positions 1991–2039 in L1
RNA, while the second binding site is located between
the RT and C domains at positions 4839–4875 of L1
RNA (Hohjoh & Singer, 1997). Notably, both of these
sites are contained within the largest RNA fragments
generated in the RNAse T1 digest of L1 RNA. Thus, it
remains possible that the p40 binding specificity is an
artifact of thein vitro assay.
The mouse L1 ORF1-encoded protein also is loc-
alized with L1 RNA in cytoplasmic RNPs (Martin,
1991). In contrast to the situation with human p40,in
vitro experiments show that the mouse ORF1-encoded
protein binds both RNA and DNA in a non-sequence
specific manner (Kolosha & Martin, 1997). Although
it remains unclear whether the mouse ORF1-encoded
protein binds L1 RNA at specific sequences, the above
studies have led to the hypothesis that cytoplasmic
RNPs are intermediates in L1 retrotransposition (see
Figure 2).
L1 ORF2 encodes a multifunctional protein con-
taining at least four conserved domains, which are, in
order from N to C terminus, an endonuclease (EN)
domain (Feng et al., 1996), a domain of unknown
function (Z) (Clements & Singer 1998), a reverse tran-
scriptase (RT) domain (Mathias et al., 1991), and a
carboxyl-terminal cysteine rich domain (C) (Fanning
& Singer, 1987). Genetic and biochemical analyses
revealed that the L1 ORF2-encoded protein contains
both RT and endonuclease activities (Feng et al., 1996;
Mathias et al., 1991). However, how ORF2 is trans-
lated, and whether the primary translation product
undergoes post-translational processing remains un-
known.
Human L1s and disease
L1 retrotranspositions first were recognized as causal
agents of disease in 1988 when two separate insertions
of 5′ truncated L1s were found to disrupt the factor
VIII gene, resulting in hemophilia A (Kazazian et al.,
1988). Since then, deleterious L1 insertions in the
human germ-line or very early in development (i.e.,
before germ cell migration) were found to result in
a variety of genetic disorders (Table 1; reviewed in
Kazazian, 1998, 1999; Kazazian & Moran, 1998).
For example, four separate truncated L1 insertions into
thedystrophingene were shown to result in muscular
dystrophy (Bakker & van Ommen, personal commu-
nication; Narita et al., 1993; Holmes et al., 1994;
Yoshida et al., 1998); whereas the insertion of dif-
ferent full-length L1s into theβ-globin or RP2 gene
were found to result inβ-thalessemia and X-linked
retinitis pigmentosa, respectively (Divoky et al., 1996;
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Figure 1. An assay to detect L1 retrotransposition in cultured mammalian cells. (A) The rationale of the assay. Candidate L1s are tagged
with an indicator cassette (mneoI) designed to detect retrotransposition events. The cassette consists of a backward copy of the neomycin
phosphotransferase gene (neo), which contains its own promoter (P′) and polyadenylation signal (A′). The backwardneogene is interrupted by
an intron in the same transcriptional orientation of the L1 and the splice donor (SD) and splice acceptor sites (SA) are indicated. Transcription
of L1 RNA from either its own promoter in the 5′UTR (light gray box) or a heterologous promoter (P) and subsequent RNA splicing results in
the production of a polyadenylated mRNA. The ORF1- and ORF2-encoded proteins can be translated from the mRNA, but the splicedn ogen
cannot be translated because it is backward. G418-resistant (G418R) colonies only will arise if the mature L1 mRNA is reverse transcribed
(RT) and integrated at a new genomic location. The retrotransposed indicator gene then can be expressed from its own promoter (P′) to produce
a transcript, which can be translated to generate a functional neomycin phosphotransferase protein. Conserved domains in the L1-encoded
proteins are described in the text. The variable length target site duplications flanking an L1 are denoted with arrows. (B) Results of a typical
retrotransposition assay. Results from a typical assay with four different RC-L1s (L1.3, L1Rp L1.2, and LRE2) are shown. A negative control
construct containing a point mutation in the L1 RT domain also is depicted.
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Figure 2. A working model for L1 retrotransposition. This model is adapted from Kazazian and Moran (1998). Question marks indicate steps
in the pathway that remain unknown. Specific details are provided in the text.
Schwahn et al., 1998). Moreover, somatic insertions
of truncated L1s into the APC tumor suppressor gene
and thec-mycproto-oncogene are implicated in colon
and breast cancer (Morse et al., 1988; Miki et al.,
1992). Interestingly, the overwhelming majority of
disease producing L1 insertions are derived from a
minor subfamily of expressed L1s denoted the Ta sub-
set (Skowronski, Fanning & Singer, 1988). Thus, the
Ta subset L1s likely account for the bulk of RC- L1s
in the human genome.
The finding that L1 can induce mutations in so-
matic cells is significant because it indicates that
L1 retrotransposition can lead to tumorigenesis (Miki
et al., 1992). Intriguingly, biochemical and immuno-
histological studies have shown that L1 RNA and p40
are elevated in certain epithelial-derived tumors (Brat-
thauer & Fanning, 1992; Bratthauer & Fanning, 1993).
Moreover, the L1 5′UTR is hypomethylated in certain
p40 producing cell lines and malignant tumors (Alves,
Tatro & Fanning, 1996; Thayer, Singer & Fanning,
1993). Whether L1 retrotransposition actually is in-
creased in tumors is unknown. However, the above
data suggest that unregulated L1 retrotransposition
may accelerate tumor progression.
In addition to being autonomously mobile muta-
gens, it is hypothesized that the proteins encoded by
RC-L1s mobilize certain SINEs (e.g., Alu elements
and tRNA derived SINEs) and processed pseudogenes,
which comprise another 10% of human DNA (Boeke,
1997; Jurka, 1997; Okada et al., 1997; Kazazian &
Moran, 1998; Gilbert & Labuda, 1999). Alu retro-
transposition can be mutagenic and 16de novoAlu
retrotranspositions either in the germ line or during
early development have been found to cause human
disease (reviewed in Deininger & Batzer 1999; Kaza-
zian, 1998; Kazazian & Moran, 1998) (Table 1). Thus,
elucidation of the mechanism of L1 retrotransposition
likely will lead to an understanding of the retrotrans-
position mechanisms utilized by other nonautonomous
retrotransposons.
It remains difficult to estimate the fraction of
human disease-associated mutations due to the in-
sertion of autonomous or non-autonomous non-LTR
retrotransposons because most mutation-detection
strategies utilize PCR and fail to detect large inser-
tions. Moreover, retrotransposition events into auto-
somes may remain unnoticed because of the hemizyg-
ous nature of the mutation. However, as of February
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Table 1. Disease-producing Alu and L1 retrotransposon insertions
Disease-producing retrotransposon insertions
L1s Alu
Disrupted Disease Insertion Ta subset L1-mediated Disrupted Disease Subfamily
gene size transduction gene
Factor VIII Hemophilia A 3.8 kb Yes No Factor IX Hemophilia B Ya5
2.2 kb No No NF1 Neurofibromatosis Ya5
681 bp Yes No FGFR2 Apert Syndrome Ya5, Yb8
(Two insertions)
APC Colon cancer 538 bp Yes Yes APC Hereditary Yb8
colon cancer
Dystrophin Duchenne 608 bp Yes No XLA X-linked Y
muscular 878 bp Yes Yes immunodeficiency
dystrophy 2.0 kb Yes No syndromes
524 bp Yes No XSCID X-linked Ya5
β-globin β-Thalessemia 6.0 kb Yes No immunodeficiency
RP2 X-linked 6.0 kb Yes No syndromes
retinitis-pigmentosa BRCA2 Breast cancer Y
CYBB Chronic 1.7 kb Yes Yes ChE Acholinesteremia Yb8
ganulomatous 1.0 kb Yes No C1 inhibitor Hypocalciuric Y
FCMD Fukuyama-type 1.2 kb Yes No hypercalcemia
congenital muscular Huntington Huntington –




GK Gycerol kinase Y
deficiency
PBGD Acute intermittent Ya5
porphyria
MLVI-2 Leukemia Ya5
Dr. Haig H. Kazazian maintains a complete database of new disease-producing retrotransposon insertions at the following address:
www.med.upenn.edu/genetics/faculty/primary/hkazazian 2.html. The disrupted genes and resulting diseases are noted. The subfamily that
gave rise to the retrotransposon insertion in noted. Two additional SINE disease-producing insertions into the FCMB (Fukuyama muscular
dystrophy gene) and the BTK (Bruton X-linked a gammaglobulinemia gene) are not included in the table, but are available at the above
internet address.
2000, 31 of the 19,687 spontaneous mutations (1 in
635) characterized in humans are due to the insertion
of non-LTR retrotransposons (Table 1 and legend).
An assay to detect L1 retrotransposition in
cultured cells
In 1996, we developed a genetic assay to study
L1 retrotransposition in cultured human cells (Moran
et al., 1996). First, we tested whether the likely pro-
genitors of disease producing insertions in the factor
VIII and dystrophin genes (L1.2 and LRE2) were in-
deed autonomous retrotransposons (Dombroski et al.,
1991; Holmes et al., 1994). To accomplish this, a
reporter cassette (mneoI) designed to detect rare retro-
transposition events was subcloned into their 3′ UTR
to createL1.2mneoIand LRE2mneoI, respectively
(Freeman, Goodchild & Mager, 1994) (Figure 1A).
The mneoIreporter cassette consists of an antisense
copy of a selectable marker (neo), the SV40 promoter
(P′), and a polyadenylation signal (A′). In addition,
the neogene is disrupted by an intron (IVS 2 of the
γ-globin gene) in the opposite transcriptional orient-
ation. This arrangement ensures that G418-resistant
cells (G418R) will arise only when a transcript initi-
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ated from the promoter drivingL1.2mneoIexpression
(P) is spliced, reverse transcribed, reintegrated into
chromosomal DNA, and expressed from promoter P′.
Transcripts that originate from P′ cannot be spliced,
the neo gene product cannot be synthesized, and the
cells will remain sensitive to G418 (G418S).
Using the above assay, we demonstrated that both
L1.2 and LRE2 could retrotranspose from an extra-
chromosomal episome into HeLa genomic DNA at
a high frequency (Moran et al., 1996). Point muta-
tions in conserved domains of the L1.2 ORF1 and
L1.2 ORF2 encoded-proteins reduced retrotranspos-
ition by 2–3 orders of magnitude (Figure 1B), and
the characterization of fourL1.2mneoI integration
events revealed the hallmarks of retrotransposition
(Moran et al., 1996). However, the target site du-
plications flanking two of these newly inserted ele-
ments were somewhat unusual. They were longer
(34 bp and 214 bp, respectively) than the target site
duplications flanking genomic L1s. Thus, it remains
formally possible that the placement of themneoIin-
dicator cassette in the L1 3′UTR adversely affects
the integration process. However, our data demon-
strate that we can, for the most part, faithfully re-
constitute L1 retrotransposition in cultured human
cells.
Applications of the cultured cell
retrotransposition assay
Identification of other L1s in the human and mouse
genomes
An immediate use of the cultured cell retrotransposi-
tion was to identify other RC-L1s from both the human
and mouse genomes. During the characterization of
L1.2, 15 other full-length L1s belonging to the Ta
subset also were identified (Dombroski et al., 1991;
Dombroski, Scott & Kazazian, 1993; Sassaman et al.,
1997). Nine of those elements encoded a reverse tran-
scriptase activity, as monitored in a heterologous yeast
expression system (Dombroski et al., 1994; Sassaman
et al., 1997), and nine contained intact open reading
frames (Sassaman et al., 1997). Subsequent analysis
revealed that five of those L1s were retrotransposition-
competent, and those data were used to estimate
that there are 30–60 RC-L1s present in the human
genome.
Two L1s, L1.3 and L1.4, yielded G418R foci at
frequencies∼10-fold greater than L1.2. Interestingly,
L1.3 and L1.2 only differ at four amino acid positions
(Dombroski, Scott & Kazazian, 1993; Sassaman et al.,
1997). Thus, it is likely that all or a subset of these
amino acid substitutions account for the dramatic
difference in their retrotransposition. One intriguing
possibility is that these amino acid substitutions (or
a subset of substitutions) alter the processivity of the
ORF2-encoded RT.
Recently, two other full-length human L1s (L1βthal
and L1Rp) were identified as mutagenic insertions into
theβ-globin and retinitis pigmentosa-2 genes, respect-
ively (Divoky et al., 1996; Schwahn et al., 1998).
Subsequent studies revealed that both L1βthal and L1Rp
could retrotranspose in cultured cells (Kimberland
et al., 1999). Thus, to date, nine active human L1s have
been identified. Though it remains possible that some
of these L1s will be immobile because they reside in
non-transcribed chromatin, it now is apparent that the
human genome contains numerous RC-L1s. Clearly,
the completion of the human genome project will lead
to the discovery of even more RC-L1s.
The identification of RC-L1s in the mouse genome
was due, in a large part, to serendipity. In 1994, the
spastic mouse was found to result from a full-length
L1 insertion (L1spa) into the glycine receptorβ-subunit
gene (Kingsmore et al., 1994; Mulhardt et al., 1994);
whereas in 1996, the Orleans reeler mouse was found
to result from a full-length L1 insertion (L1orl) into
the reeler gene (Takahara et al., 1996). Since both
of those L1s contained open reading frames, they
became immediate candidates for retrotransposition-
competent elements. Both L1spa and L1orl readily
retrotransposed in the cultured cells, and DNA se-
quence analysis revealed that those elements belonged
to a new subfamily (Tf) of mouse L1s (Naas et al.,
1998; Saxton & Martin, 1998). Interestingly, sub-
sequent studies revealed that seven of 11 (63%) full-
length Tf elements randomly isolated from a mouse
genomic DNA library were able to retrotranspose in
cultured cells (DeBerardinis et al., 1998). Since there
are approximately 2400 full-length Tf elements in the
genome ofmus domesticus, these data suggest that up
to 1500 mouse Tf elements remain retrotransposition-
competent.
We also demonstrated that human L1s can retro-
transpose in cultured mouse L cells (Moran et al.,
1996) and that mouse L1s readily retrotranspose in
human Hela cells (Naas et al., 1998). Although it is
possible that L1 encodes all of the functions required
for its retrotransposition, it is likely that retrotranspos-
ition is facilitated by host-encoded cellular factors. If
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so, our data would suggest that some of these factors
are conserved between rodents and humans.
Identification of other essential and non-essential
sequences within L1
The cultured cell retrotransposition assay also has
been instrumental in identifying conserved func-
tional domains within the L1-encoded proteins re-
quired for retrotransposition. In collaboration with
the Boeke laboratory, we demonstrated that the
amino terminus of L1 ORF2 encodes a novel endo-
nuclease (EN) required for retrotransposition (Feng
et al., 1996). The endonuclease motif resembles the
apurinic/apyrimidinic (AP) endonucleases, but shows
no preference for abasic sites. Instead, L1 EN pref-
erentially cleaves the sequence 5′PO4-TTT/AA-3 ′OH
(where / denotes the insertion site), which resembles
many in vivo L1 integration sites (Feng et al., 1996;
Moran et al., 1996). The purified protein can gen-
erate site-specific 5′ PO4 and 3′OH nicks either in
supercoiled plasmids or in oligonucleotide substrates
containing the recognition site (Cost & Boeke, 1998;
Feng et al., 1996). Moreover, site-directed point muta-
tions in conserved residues of L1 EN abolish this
nicking activity in vitro and reduce L1 retrotransposi-
tion in cultured cells by 2–3 orders of magnitude (Feng
et al., 1996). Thus, we propose that L1 is a site-
specific retrotransposon that integrates preferentially
at DNA sequences cleaved by L1 EN by a template
DNA-primed reverse transcription mechanism (TPRT)
(Luan et al., 1993; Figure 2; see below).
A parallel analysis further revealed that the L1
endonuclease-like domain is conserved among non-
LTR retrotransposons from a wide variety of organ-
isms, suggesting that those elements also retrotrans-
pose by a similar TPRT mechanism (Martin et al.,
1995; Feng et al., 1996). Indeed, the EN domain of
the R1Bm element fromBombyx moriencodes a site-
specific endonuclease, which likely is needed for its
retrotransposition (Feng, Schumann & Boeke, 1998).
Notably, though our study shows that L1 encodes
an endonuclease likely required for its retrotransposi-
tion, it remains possible that L1 sometimes can utilize
pre-existing nicks in chromosomal DNA to mediate
its integration through an endonuclease independent
pathway (Branciforte & Martin, 1994).
Comparative biological approaches also have been
used to identify both conserved regions in L1 RNA
and conserved amino acid residues in the L1-encoded
proteins, which were hypothesized to be important for
retrotransposition (Fanning & Singer, 1987; Xiong &
Eickbush, 1990). The cultured cell assay now allows
a rapid means to test many of those hypotheses ex-
perimentally. For example, we showed that conserved
amino acids in the carboxyl terminus of the L1 ORF1-
encoded protein are required for retrotransposition.
Since ORF1 encodes an RNA binding protein, it is
tempting to speculate that these amino acids play a
crucial role in binding p40 to its nucleic acid template
(Moran et al., 1996). We also demonstrated that the
L1-ORF2 cysteine-rich domain provides a function re-
quired for retrotransposition, which is distinct from the
L1 RT or L1 EN activity (Moran et al., 1999b). Again,
it is tempting to speculate that these mutations affect
binding of ORF2 to either L1 RNA or genomic DNA
(Moran et al., 1996).
Interestingly, our studies also uncovered regions
of L1, which apparently are dispensable for retro-
transposition. For example, deletion of a conserved
polypurine tract within the L1 3′UTR did not effect L1
retrotransposition (Moran et al., 1996). This finding
remains somewhat enigmatic because: 1) the 3′UTRs
of rat and mouse L1s also contain a conserved poly-
purine tract (Usdin & Furano, 1989); and (2) the
3′UTR of other non-LTR retrotransposons (notably
R2Bm from Bombyx mori) functions as acis-acting
docking site for binding the element encoded RTin
vitro (Luan et al., 1993). By the strictest definition, our
data suggest that the 3′UTR neither is required for hu-
man L1 retrotransposition in cultured cells nor serves
as a required binding site for the L1 RT. However, it
remains formally possible that the L1 3′UTR functions
in vivo to: (1) bind factors to help define the L1 pA
site; (2) function in L1 RNA localization or transla-
tion; and (3) aid in the L1 integration process. Indeed,
the unorthodox target site duplications observed in
two of four characterized integration events (see pre-
vious section) may occur because the L1 3′UTR is
interrupted by themneoIindicator gene.
We also demonstrated that the L1 5′UTR could be
replaced with a heterologous viral promoter (either the
cytomegalovirus immediate early promoter (CMV) or
the Rous sarcoma virus LTR (RSV)) and that the
resultant constructs could retrotranspose efficiently
(Moran et al., 1996). Therefore, we conclude that an
RNA polymerase II transcript can serve as an inter-
mediate in L1 retrotransposition. Moreover, our data
show that L1 can retrotranspose from a heterologous
transcript whose 5′ end is derived from non-L1 DNA
sequences (Moran et al., 1996). Thus, it is possible
that L1 can retrotranspose non-L1 sequences derived
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from its 5′ flank to new genomic locations. Together,
the above data are in accord with previous studies and
suggest that the major function of the L1 5′ UTR is
to serve as a promoter for L1 transcription (Swergold,
1990; Minakami et al., 1992; Kurose et al., 1995).
Unexpected findings uncovered from the cultured
cell retrotransposition assay
The cultured cell assay also has yielded unexpec-
ted information about L1 retrotransposition. First, we
found that 5–10% of new L1 retrotransposition events
in cultured cells occurs into the introns of actively
transcribed genes (Moran, DeBerardinis & Kazazian,
1999a). Data from the Washington University genome
center estimate that 15% of human DNA consist of
genes (exons plus introns; Ian Korf, personal commu-
nication). Thus, our findings suggest there is not an
active mechanism to preclude L1 from retrotranspos-
ing into genes.
The finding that L1 could readily retrotranspose
into genes was somewhat surprising based on earlier
studies, which demonstrated that L1 predominates in
AT rich non-transcribed heterochromatin (Korenberg
& Rykowski, 1988). However, those studies are sub-
ject to selective pressures that have operated on the
accumulation of L1s during human genome evolution.
Clearly, L1 can be a mutagen. Thus, over evolutionary
time, it is likely that L1 retrotransposition events into
intergenic regions would be tolerated more easily than
L1 insertions into genes. This effective ‘neutrality’
could, in principle, lead to the preponderance of L1 se-
quences in heterochromatin. Alternatively, there may
exist yet undiscovered recombination-based mechan-
isms to remove L1s (as well as other DNA sequences)
from the human genome.
Since our study detects only new L1 retrotransposi-
tion events, it likely reflects L1 integration preferences
quite accurately. The completion of the human gen-
ome project undoubtedly will enable a thorough ana-
lysis of the genomic distribution of L1 sequences. In
fact, it will be interesting to determine whether recent
L1 insertions (such as those derived from the Ta sub-
set) are dispersed randomly throughout the genome or
are clustered in specific chromosomal regions.
We also demonstrated that L1 could efficiently
retrotranspose non-L1 DNA derived from its 3′ flank
to new genomic locations (Figure 3; Moran, DeBer-
ardinis & Kazazian, 1999a). In principle, this process
(termed L1-mediated transduction) provides a simple
mechanism to introduce non-L1 sequences (such as
exons or promoters) into existing genes. L1-mediated
transduction is unique because:
(1) it does not depend on homologous DNA se-
quences;
(2) the relative genomic positions of the ‘shuffled’
sequences essentially are irrelevant;
(3) it occurs via an RNA intermediate; thus, the ori-
ginal ‘donor sequence’ will not be changed by the
process; and
(4) it allows a mechanism to exchange delimited
amounts of genetic information between non-
homologous chromosomes, providing a powerful
means to generate diversity in randomly mating
sexual populations.
Furthermore, since most L1s are 5′ truncated, it
is likely that some L1-mediated transduction events
leave no trace of L1 sequence (see middle panel in
Figure 3). Indeed, our data predict that some processed
pseudogenes and microsatellite markers may have
arisen or been amplified by L1-mediated transduction.
Initially the finding that L1 could readily retro-
transpose DNA derived from 3′ flanking sequences
was a surprise. However, upon reflection, our data is
explained rather easily. First, L1 undergoes unortho-
dox polyadenylation because the polyA tail is added
directly to the 5′- AAUAAA-3 ′ CPSF (cleavage and
polyadenylation specificity factor) binding site (Col-
gan & Manley, 1997). In addition, conserved elements
that reside downstream of standard RNA polymerase
II cleavage and polyA addition sites clearly are absent
in L1. Thus, we propose that the L1 polyadenyla-
tion (L1 pA) site is ‘weak’, and can be bypassed
if ‘stronger’ pA sites are present in 3′ flanking ge-
nomic sequences. Indeed, perhaps the presence of a
‘weak’ pA site allows L1s to reside within introns and
not wreak havoc on gene expression (Moran, DeBer-
ardinis & Kazazian, 1999a). Notably, the ability of L1
readthrough transcripts to retrotranspose further sup-
ports our hypothesis that the L1 poly A tail, and not
RNA sequences in the 3′ end of L1 RNA, is critical
for retrotransposition (Moran et al., 1996).
Retrotranspositions derived from readthrough L1
transcripts also have been identifiedin vivo (Table 1).
The first occurrence was published in 1992, when a
mutagenic insertion into the APC gene was accompan-
ied by 23 bp of non-L1 sequence (Miki et al., 1992).
However, these data were clearly overlooked. The
phenomenon of L1-mediated transduction became ap-
parent in 1994, when a mutagenic insertion into the
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Figure 3. L1-mediated transduction (adapted form Moran et al., 1999). A retrotransposition-competent L1 resides at a chromosomal location
denoted by the white bar at the top of the figure. The native L1 pA site and a fortuitous pA site in 3′ fla king DNA are denoted by the gray and
black lolipops, respectively. In principle, three types of L1-mediated transduction events can occur if the L1pA site is bypassed and the pA site
in flanking DNA is utilized. Each type of event is described in the text and is noted in the figure. The gray arrows flanking L1 (top) represent
the original target site duplications flanking the element. New target site duplications generated by the retrotransposition of a readthrough L1
transcript are denoted with the black arrows (bottom figures). Non-homologous chromosomes are indicated by the different shading patterns.
dystrophin gene was accompanied by 489 bp of non-
L1 sequence (Holmes et al., 1994). More recently,
a mutagenic L1 insertion causing chronic granulo-
matosis disease also likely arose from the retrotrans-
position of a readthrough transcript (Meischl, Boer &
Roos, 1998). Since three of 13 (23%) of L1 insertions
in human disease genes are derived from readthrough
transcripts, we predict that a detailed analysis of mam-
malian genomes should reveal many more examples
of L1-mediated transduction events. Indeed, a prelim-
inary examination of human DNA sequences depos-
ited in public databases suggests that up to 15% of
L1s arose via the retrotransposition of a readthrough
transcript (Goodier, Ostertag & Kazazian, 2000).
Interestingly, L1-mediated transduction does not
seem specific for members of the Ta subset. Two
ancient human L1 insertions likely resulted from
the retrotransposition of a readthrough transcript
(McNaughton et al., 1997; Rozmahel et al., 1997).
Moreover, a full-length A-type L1 transcript from
RNPs from mouse F9 cells was shown to contain
about 1 kb of 3′ flanking sequence (Martin, 1994).
Subsequent analyses demonstrated that this transcript
was derived from a contiguous sequence in mouse
genomic DNA, indicating that it likely represents an
authentic example of L1-mediated transduction. Thus,
we conclude that L1-mediated transduction occurs in
mouse and man, and it is likely that the process has
an ancient origin. However, the extent to which this
process impacted mammalian genome evolution, and
whether L1-mediated transduction actually can lead
to the evolution of new genesin vivo remains to be
determined.
A working model for L1 retrotransposition
The similarity of the RTs encoded by non-LTR retro-
transposons from different organisms suggests that
these elements retrotranspose by similar mechanisms.
The best model for non-LTR retrotransposition comes
from studies of a site-specific non-LTR retrotrans-
poson (R2Bm) found in the ribosomal DNA of the
silkworm Bombyx mori(Luan et al., 1993).In vitro
biochemical studies conducted in the Eickbush labor-
atory showed that R2Bm encodes a single protein
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with both sequence specific endonuclease and reverse
transcriptase activities (Luan et al., 1993; Xiong &
Eickbush, 1988b). The R2Bm protein can generate a
site-specific endonucleolytic nick in target DNA to lib-
erate a 3′ hydroxyl (OH) that subsequently is used by
the R2Bm protein as a primer to reverse transcribe the
3′ end of R2Bm RNA (Luan et al., 1993). This mode
of priming is termed target site DNA-primed reverse
transcription (TPRT).
Studies of mobile group II introns support the gen-
eral TPRT retrotransposition model for non-LTR retro-
transposon. Genetic experiments demonstrate that cer-
tain group II introns are site-specific retrotranspo-
sons, which can move from intron-containing alleles
to intronless alleles by a process termed homing
(Lazowska, Meunier & Macarde, 1994; Moran et al.,
1995). Mobile group II introns encode a multifunc-
tional protein that promotes their splicing (maturase
activity) (Carignani et al., 1983; Moran et al., 1994)
and mobility (reverse transcriptase and site-specific
endonuclease activities) (Kennell et al., 1993; Moran
et al., 1995; Zimmerly et al., 1995a,b). Mobility is
initiated by an endonuclease containing the intron-
encoded protein and the excised intron RNA and oc-
curs by a two step process (Zimmerly et al., 1995a,b).
First, the sense strand of recipient DNA is cleaved
precisely at the exon junction by a partial or a com-
plete reverse splicing of the intron RNA. Second,
the antisense strand is cleaved 10 nucleotides down-
stream by the intron-encoded endonuclease to liberate
a 3′ hydroxyl residue, which is used as a primer for
the reverse transcription of the intron RNA by the
intron-encoded RT.
Our work supports the notion that L1 retrotrans-
position also occurs by TPRT (Kazazian & Moran,
1998) (see Figure 2). First, RC-L1s are transcribed
from an internal promoter located in the 5′UTR (Kur-
ose et al., 1995; Minakami et al., 1992; Swergold,
1990). Next, the bicistronic L1 RNA is transported to
the cytoplasm, where it is translated (Leibold et al.,
1990; McMillan & Singer 1993). It is hypothesized
that the L1 encoded proteins bind to the RNA from
which they were translated (Moran et al., unpublished
data) to form a cytoplasmic RNP – a proposed in-
termediate in the retrotransposition process (Martin,
1991; Hohjoh & Singer, 1996, 1997). However, how
RNPs are formed and whether the particles contain the
ORF2-encoded protein remains uncertain.
After its formation, the L1 RNP presumably is
transported to the nucleus to carry out retrotranspos-
ition. It is not known whether p40 and the ORF2-
encoded protein are critical to the transport of L1
RNA into the nucleus, or whether L1 RNA bound to
ORF2 protein reaches chromatin passively after nuc-
lear breakdown in mitosis. However, it is likely that
L1 retrotransposition occurs by TPRT. We hypothesize
that the L1 endonuclease nicks chromosomal DNA at
the sequence 5′PO4-TTT/AA-3 ′OH (where / denotes
the cleavage site). The liberated 3′ hydroxyl residue
then is thought to act as a primer for reverse transcrip-
tion of the L1 RNA by the L1 RT (Figure 2; Feng
et al., 1996). Subsequent steps in the retrotransposition
pathway such as second strand cleavage, second strand
DNA synthesis, and ligation of the resultant cDNA to
genomic DNA all remain to be explained.
Potential limitations of the cultured cell
retrotransposition assay
The cultured cell L1 retrotransposition assay has en-
abled the identification of RC-L1s in both the human
and mouse genomes, and has revealed functional do-
mains within the L1-encoded proteins. Moreover, we
also have uncovered a novel mechanism by which L1
retrotransposition can contribute to genome diversity.
However, the cultured cell assay has some potential
limitations.
First, activation of themneoIgene requires RNA
splicing. Since L1s normally lack introns, it remains
possible that the presence of the indicator cassette di-
verts L1 RNA from a splicesome-independent to a
splicesome-dependent RNA export pathway (Stutz &
Rosbash, 1998). Thus, the presence and function of
RNA export signals in L1 RNA may be compensated
for by the artificial inclusion of an intron into L1 RNA.
Next, in every instance, we have assayed for L1
retrotransposition in transformed somatic mammalian
cultured cells, which have an abnormal karyotype. It
will be interesting to determine whether L1 actually
can retrotranspose in non-transformed somatic cells or
embryonic stem cells. Indeed, the somatic insertion
into the APC gene suggests that a subset of L1s can
retrotranspose in somatic cells (Miki et al., 1992).
Finally, in every instance we have assayed for
L1s ability to retrotranspose from an extrachromo-
somal episome to genomic DNA. Thus, all of these
L1s have been placed in a privileged expression con-
text. It remains possible that some of those RC-L1s
are integrated in transcriptionally-repressed regions of




We just are beginning to realize the consequences of
L1 retrotransposition on the human genome. Clearly,
L1 is a mutagen. Moreover, because of the abundance
of L1s, it is likely that they provide scaffolds for ille-
gitimate recombination, which may contribute to the
genome instability seen in many tumors. Thus, with
a fundamental mechanistic knowledge of L1 biology,
we will gain a further understanding of both the mo-
lecular mechanisms that underlie human disease and
the molecular processes that helped sculpt mammalian
genomes.
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